FIKSIROVANNAYa KOMBINATsIYa BEKLOMETAZONA PROPIONATA I FORMOTEROLA -PERSPEKTIVNAYa AL'TERNATIVA V TERAPII BRONKhIAL'NOY ASTMY
- Authors: Nazarova E.V1, Kurbacheva O.M1
-
Affiliations:
- Issue: No 3 (2014)
- Pages: 81-85
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286645
- ID: 286645
Cite item
Open Access
Access granted
Abstract
Traditionally, bronchial asthma (BA) has been considered as a disease of large and medium bronchi, and small airways received little attention. Recently, however, there is clear evidence that the inflammatory process in bronchial involves distal lower respiratory tract. Currently, inhalation devices to improve the delivery of anti-inflammatory drugs on the periphery of the lungs are actively developed. This determines the possibility of improving the results of long-term treatment of patients with bronchial asthma. In the case of ineffectiveness of treatment of bronchial asthma with low doses of inhaled glucocorticosteroids (IGCS), modern guidelines recommend combination of inhaled corticosteroids and LABA (long-acting β2-agonists) as the «gold» standard, and the benefits of appointment of two drugs in one inhaler are noted. Foster is the unique drug that combines IGCS and LABA in a single inhaler with ultrafine dispersion represented on the Russian market; it fixed combination of beclomethasone propionate and formoterol fumarate.
Full Text
About the authors
E. V Nazarova
Email: evallergo@yandex.ru
O. M Kurbacheva
Email: kurbacheva@gmail.com
References
- Asthma. Quick asthma facts and The Faces of asthma. Geneva: World Health Organization; 2010. Available from: http://www.who.int/respiratory/asthma/en/
- GINA (Global initiative for asthma).Global strategy for asthma management and prevention. NHLBI/WHO workshop report. Bethesda: National Institutes of Health, National Heart Lung and Blood Institute, Updated 2011.
- Княжеская Н.П. Эффективность и безопасность формотерола дозированного аэрозольного ингалятора ГФА-134а на основе технологии Модулит. Consilium medicum. 2008; 10(3): 80-5.
- Цой А.Н. Фиксированная комбинация ультрамелкодисперсных дозированных аэрозолей беклометазона дипропионата/формотерола: слагаемые успеха. Consilium medicum. Пульмонология. 2008: С. 39-45.
- Chiesi Pharmaceutici SpA. Modulite®: the value of Chiesis technolgy in the treatment of asthma and COPD (online). Available from URL: http://www.chiesigroup.com (Accessed 2006 May 25).
- Mauad T., Silva L.F.F., Santos M.A., et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am. J. Respir. Crit. Care Med. 2004; 170: 857- 62.
- Busacker A., Newell J., Keefe T., et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest. 2009; 135(1): 48-56.
- Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids. New Developments. Am. J. Respir. Care Med. 1998; 157(3): 1-53.
- Singh D., Piccinno A., Borrill Z., et al. Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. Pulm. Pharmacol. Ther. 2008; 21(3): 551-57.
- Thongngarm T., Silkoff P.E., Kossack W.S., Nelson H.S. Hydrofluoroalkane 134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J. Asthma. 2005; 42: 257-63.
- Hampel F., Lisberg E., Guerin J.C. Effectiveness of low doses (50 and 100 μg b.i.d) of beclomethasone dipropionate delivered as a CFC free extrafine aerosol in adults with mild to moderate asthma. Study Group. J. Asthma. 2000; 37: 389-98.
- Goldin J.G., Tashkin D.P., Kleerup E.C., et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin section computed tomography. J. Allergy Clin. Immunol. 1999; 104: 258-67.
- Ohbayashi H. One year evaluation of the preventative effect of hydrofluoroalkane beclomethasone dipropionate on eosinophilic inflammation of asthmatic peripheral airways. Respiration. 2007; 74: 146-53.
- Van Schayck C.P., Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane beclometasone diproprionate extrafine aerosol) in asthma (part 1): an update of clinical experience in adults. Int. J. Clin. Pract. 2004; 58: 678-88.
- Bonnet Gonod F., Kottakis I., Ballabio M., et al. Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate / formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study. 16th Annual Congress of the European Respiratory Society; 2006 Sep. 2-6; Munich: P1237.
- Huchon G., Magnussen H., Chuchalin A., et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir. Med. 2009; 103: 41-9.
- Scichilone N., Battaglia S., Sorino C., et al. Effects of extrafine inhaled beclomethasone / formoterolon both large and small airways in asthma. Allergy. 2010; 65: 897-902.
- Papi A., Paggiaro P., Nicolini G., et al. Beclomethasone / formoterol vs fluticasone / salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007; 62: 1182-88.
- Papi A., Paggiaro P.L., Nicolini G., et al. Beclomethasone / formoterol versus budesonide / formoterol combination therapy in asthma. Eur. spir. J. 2007; 29: 682-89.
Supplementary files
